American Thoracic Society - Sanofi Investor Call
sanofi
Itepekimab: First IL-33 in COPD with unprecedented exacerbation
reduction in former smokers with and without Type 2 inflammation
Former smokers into 20 weeks post-treatment period¹
42.4% RRR
P=0.0081
45.2% RRR
P=0.0488
43.2% RRR
P=0.0023
1,6
1,4
1,2
1,0
0,8
0,6
0,4
0,2
0,0
Treatment Period
Post-treatment (20 weeks)
Combined
Placebo
Itepekimab
> >40% reduction in exacerbations in
former smokers
• Effect present in both high and low eosinophil
population
Sustained efficacy 20 weeks post treatment
Only member of IL-33/ST2 class with
clinical data in COPD
• Itepekimab was well tolerated in ph2a
study
1. Rabe et al. Lancet Respir Med. 2021
Itepekimab is under investigation and not yet approved by any regulatory agency.
37 ATS Investor CallView entire presentation